

CMP: ₹ 1,874

Target: ₹ 2,230 (19%)

Target Period: 12 months

BUY

December 9, 2025

Engineered for outperformance...

About the stock: Coforge Ltd (Coforge) is a digital services and solutions provider that leverages its domain experience across sectors such as Banking & Financial Services, Insurance, Government, Travel, Transport and Hospitality.

- Coforge had a strong year (FY25) with revenue growth of 31.2% in dollar terms & rupee revenue growth of 33.5%.

Investment Rationale:

- Hyper-specialisation + Large-deal engine driving growth:** We attended Coforge's Investor Day 2025, wherein the management highlighted Coforge's proactive, non-RFP (request for proposal) large-deal strategy and deep domain specialisation across BFS, Insurance, Travel and Healthcare which position it for sustained industry-leading growth into FY28E. **Coforge closed 6 large deals in H1FY25 and is targeting 20 by year-end, with cloud and AI embedded in two-thirds of wins.** Travel is set for a "deep acceleration" in the next 12 months, while Healthcare/Lifesciences emerges as the next scalable growth wave as it grows beyond ARR of US\$100 mn, with focus on the payers and medtech space and probabilistic opportunities seen in lifesciences and provider segments. **We expect US\$ revenue to grow at CAGR of 17.4% over FY25-28E.**
- Strong margin visibility and cash generation:** Management reiterated the 14% EBIT trajectory (with no further one-offs hitting the P&L going ahead) and expects $\geq 70\%$ quarterly FCF/PAT consistently, supporting stable reinvestment. With no plans for new geographies or service lines over the next 3–5 years, focus remains on execution excellence, deal shaping and disciplined capital deployment. **Accordingly, we bake in EBIT margins of 13.5%/13.7%/14.2% in FY26E/FY27E/FY28E respectively.**
- AI-led differentiation strengthening competitive moat:** AI execution is now a core driver of velocity and wallet share expansion. Platforms like **Quasar, ForgeX and TrustAI** are compressing delivery timelines and enabling Coforge to win complex legacy-modernisation mandates such as the US\$1.56 bn Sabre mega deal in the TTH vertical. Moreover, testing (Cigniti), contrary to market fears, remains a high-growth segment, aided by 80%+ automation through **Blueswan**. This AI-first engineering stack enhances win-rates, boosts account mining and supports Coforge's premium pricing and growth resilience.

Rating and Target Price

- We continue to believe that the company's diversified business mix and strong execution engine position it well to sustain above-industry growth levels, even amid macro uncertainties.
- We maintain **BUY** rating on Coforge with revised target price of **₹2,230 (vs 2,110 earlier)** as we roll over to FY28E; valuing it at 35x on FY28E EPS.

Coforge


Particulars

Particular	Amount
Market Capitalisation (₹ Crore)	62,807
Total Debt (₹ Crore)	6.7
Cash & Investment (₹ Crore)	1,028.9
EV (₹ Crore)	61,784
52 week H/L	2005/ 1194
Equity capital	66.9
Face value	2.0

Shareholding pattern

	Dec-24	Mar-25	Jun-25	Sep-25
Promoters	-	-	-	-
FII	43	40	37	34
DII	48	50	52	55
Other	10	10	10	11

Price Chart



Key risks

- Lower than expected revenue and margin expansion;
- Slower than expected pipeline to deal conversion

Research Analyst

Bhupendra Tiwary, CFA
bhupendra.tiwary@icicisecurities.com

CA Anjini Sharma
anjini.sharma@icicisecurities.com

Key Financial Summary

Financials	FY23	FY24	FY25	5 Year CAGR (FY20-25)	FY26E	FY27E	FY28E	3 year CAGR (FY25-28E)
Net Sales	8,015	9,179	12,051	NC	16,017	18,553	20,912	20.2%
EBITDA	1,405	1,505	1,998	NC	2,841	3,247	3,743	23.3%
EBITDA Margins (%)	17.5	16.4	16.6		17.7	17.5	17.9	
Net Profit	694	808	839	NC	1,501	1,883	2,212	38.1%
Diluted EPS (₹)	20.7	130.8	127.2		43.3	54.3	63.8	
P/E	90.3	71.5	73.5		43.2	34.5	29.3	
RoNW (%)	22.5	22.3	13.2		20.8	22.8	23.4	
RoCE (%)	27.9	23.6	15.4		19.8	21.6	22.8	

Source: Company, ICICI Direct Research; Note: FY25 numbers are excluding AdvantageGo divestment and thus not comparable (NC)

Key Investor Day highlights

- Management remains highly confident about FY26 demand, calling out a “deep acceleration” in Travel and strong momentum in Healthcare/Lifesciences. 95% repeat business; client budgets viewed as “elastic” tied to value delivered. Growth engine anchored in hyper-specialisation across BFS, Insurance, Travel and increasing focus on Healthcare and UK public sector.
- **Margin and outlook:** 14% EBIT margin trajectory reiterated with no further one-offs. Further, formal guidance for both revenue and margins to stop from FY27, but execution framework remains unchanged. Notably, no new geographies, industries or service lines planned for the next 3–5 years as focus remains on scaling existing pillars.
- **BFS vertical:** The focus has shifted to geos outside of North America such as EMEA and APAC. Moreover, non-discretionary spends areas such as payments, financial crime and compliance, regulatory change management and asset servicing within BFS are being targeted to maintain strong growth amid weak macro.
- **Travel vertical:** Strong pipeline for accelerated growth in the next 12 months; US\$15bn opportunity in modern airline retailing via Aeronova.ai solution
- **Healthcare & Lifesciences:** Highlighted as the next major growth wave with focus on the payers and medtech space and probabilistic opportunities in lifesciences and provider segments.
- **FCF/PAT:** FCF/PAT $\geq 70\%$ expected each quarter; strong cash generation remains intact.
- **Inorganic expansion:** Cigniti acquisition (\$219mn) to close in 4–6 weeks; future acquisitions will remain contrarian and be scaled, EPS-accretive (from year 1), and focused on client access and scaling rather than capability addition.
- **Large deals:** Closed 6 large deals in H1; targeting 20 by FY25-end, with proactive deal shaping (non-RFP).
- **AI platforms** – Quasar, ForgeX, TrustAI now embedded across delivery; accelerating timelines and enabling large modernization deals.
- **Testing market** expanding to US\$132bn by 2032 from US\$ 57bn in 2025; Coforge gaining share with 80%+ automation via Blueswan. Overall quality engineering (QE) and testing market remains in good shape.
- **Cloud and AI** present in two-thirds of large deals; **hyperscaler partnerships** contribute ~\$550mn annually with triple-digit YoY growth (i.e., 100%+ YoY growth).

Exhibit 1: Change in Estimates

(₹ crore)	FY26E			FY27E			FY28E
	Old	New	% Change	Old	New	% Change	Introduced
Revenue (USD mn)	1,863	1,863	0.0	2,096	2,096	0.0	2,337
Revenue	16,017	16,017	0.0	18,448	18,553	0.6	20,912
EBIT	2,176	2,159	-0.8	2,583	2,542	-1.6	2,970
EBIT Margin (%)	13.6	13.5	-12 bps	14.0	13.7	-30 bps	14.2
PAT	1,514	1,501	-0.8	1,922	1,883	-2.0	2,212
EPS	43.6	43.3	-0.8	55.4	54.3	-2.0	63.8

Source: Company, ICICI Direct Research

Financial Summary

Exhibit 2: Profit and loss statement ₹ crore

(Year-end March)	FY25	FY26E	FY27E	FY28E
Total op. Income	12,051	16,017	18,553	20,912
Growth (%)	31.3	32.9	15.8	12.7
COGS (employee expenses)	8,002	10,551	12,245	13,760
S,G&A expenses	2,051	2,625	3,061	3,409
Total Operating Expenditure	10,053	13,177	15,306	17,169
EBITDA	1,998	2,841	3,247	3,743
Growth (%)	32.8	42.2	14.3	15.3
Depreciation	428	682	705	774
Other Income (net)	(108)	(93)	(60)	(60)
PBT	1,463	2,066	2,482	2,910
Total Tax	333	458	571	669
Adjusted PAT	839	1,501	1,883	2,212
Growth (%)	4	79	25	17
Adjusted EPS (₹)	127.2	43.3	54.3	63.8
Growth (%)	(2.8)	(66.0)	25.4	17.5

Source: Company, ICICI Direct Research

Exhibit 3: Cash flow statement ₹crore

(Year-end March)	FY25	FY26E	FY27E	FY28E
Profit before Tax	1,463	2,066	2,482	2,910
Add: Depreciation	428	682	705	774
(Inc)/dec in Current Assets	(1,182)	(706)	(657)	(607)
Inc/(dec) in CL and Provisions	841	281	485	451
Taxes paid	(396)	(458)	(571)	(669)
CF from op.activities	1,237	1,865	2,443	2,858
(Inc)/dec in Investments	-	-	-	-
(Inc)/dec in Fixed Assets	(614)	(481)	(519)	(523)
Others	71	(93)	(60)	(60)
CF from inv. activities	(2,448)	(574)	(579)	(583)
Issue/(Buy back) of Equity	2,202	-	-	-
Inc/(dec) in loan funds	(87)	-	-	-
Dividend paid & dividend tax	(510)	(676)	(847)	(996)
CF from fin. activities	1,675	(676)	(847)	(996)
Net Cash flow	464	616	1,016	1,279
Exchange difference	10	-	-	-
Opening Cash	321	883	1,499	2,516
Closing Cash	796	1,499	2,516	3,795

Source: Company, ICICI Direct Research

Exhibit 4: Balance Sheet ₹crore

(Year-end March)	FY25	FY26E	FY27E	FY28E
Liabilities				
Equity Capital	67	69	69	69
Reserve and Surplus	6,312	7,140	8,176	9,393
Total Shareholders funds	6,379	7,210	8,245	9,462
Total Debt	7	7	7	7
Provisions	174	174	174	174
Minority Interest / Other NCL	2,932	3,035	3,063	3,091
Total Liabilities	9,492	10,425	11,489	12,734
Assets				
Net Block	2,253	2,052	1,867	1,616
Capital WIP	2	2	2	2
Total Fixed Assets	2,256	2,055	1,869	1,618
Goodwill	3,843	3,843	3,843	3,843
Deferred tax assets	329	329	329	329
Debtors	2,577	3,605	4,176	4,707
Other Current Assets	1,156	926	1,073	1,209
Cash	883	1,499	2,516	3,795
Current Investments	146	146	146	146
Total Current Assets	4,762	6,176	7,910	9,857
Trade payables	988	1,611	1,866	2,104
Other current liabilities	1,721	1,366	1,582	1,784
Short term provisions	71	83	97	109
Total Current Liabilities	2,780	3,061	3,545	3,996
Net Current Assets	1,982	3,116	4,365	5,860
Application of Funds	9,492	10,425	11,489	12,734

Source: Company, ICICI Direct Research

Exhibit 5: Key ratios

(Year-end March)	FY25	FY26E	FY27E	FY28E
Per share data (₹)				
Adjusted EPS (Diluted)	24.2	43.3	54.3	63.8
DPS	57	19	24	29
Cash per Share	26.8	43.2	72.5	109.4
BV per share (Diluted)	183.9	207.8	237.7	272.7
Operating Ratios (%)				
EBITDA Margin	16.6	17.7	17.5	17.9
PBT Margin	12.1	12.9	13.4	13.9
PAT Margin	7.0	9.4	10.1	10.6
Debtor days	78	82	82	82
Creditor days	30	37	37	37
Return Ratios (%)				
RoE	13.2	20.8	22.8	23.4
RoCE	15.4	19.8	21.6	22.8
RoIC	18.6	24.6	28.8	33.8
Valuation Ratios (x)				
P/E (Adjusted)	73.7	43.3	34.5	29.4
EV / EBITDA	30.9	21.5	18.5	15.7
EV / Net Sales	5.1	3.8	3.2	2.8
Market Cap / Sales	5.2	3.9	3.4	3.0
Price to Book Value	9.7	9.0	7.9	6.9
Solvency Ratios				
Debt/EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	1.3	1.5	1.5	1.5
Quick Ratio	1.3	1.5	1.5	1.5

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
Third Floor, Brillanto House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com



ANALYST CERTIFICATION

I/We, Bhupendra Tiwary, CFA, MBA (Finance), Anjini Sharma, CA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agarwal
Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Jeetu Jawrani Email address: headsservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report